Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.
|Published (Last):||5 July 2012|
|PDF File Size:||12.14 Mb|
|ePub File Size:||15.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
Interestingly, in addition to a relevant percentage of hematological remission, some patients also experienced a molecular remission. In these review, the characteristics important for the diagnosis and categorisation of B-cell lymphomas will be summarised.
Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases. Am J Clin Pathol. Nonimmunoglobulin gene hypermutation in germinal esplenivo B cells. Finally, the classification must be histopathologically based because it is the pathologist who, in most instances, makes the initial diagnosis.
LEZM – Linfoma Esplénico de la Zona Marginal
A longer follow-up and the study of a larger group of patients are warranted to confirm our findings. Two out three patients, who received pentostatin as first line therapy, ttained a complete response CR. Cutaneous margina of follicular lymphomas.
Because of the indolent course of the disease, monotherapy with rituximab has previously been proposed. Ssplenico the complete responders seven patients had also a molecular remission. The role of rituximab as maintenance therapy, in order to prolong the time that elapses until progression occurs, still needs to be confirmed.
Orphanet: Linfoma esplenico de la zona marginal
Our results suggest that this schedule is well tolerated and could be an useful alternative to splenectomy. The majority of symptomatic patients undergo splenectomy, while a few receive first-line chemotherapy, especially with purine analogues. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Cell cycle deregulation in B-cell lymphomas. Extramedullary tumors of lymphoid or esplejico blasts.
Puede estar infiltrada la medula pero con buena reserva medular. With a median follow-up of 35 month the median overall survival OS is 40 month and the median progression free survival PFS is 18 month. Date of first submission: A chest CT scan revealed mediastinal enlargement. CD 10 y bcl-6, la t 14; Are you a health professional able to prescribe or dispense drugs? The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or 11 Grupo Asturiano de Linfomas Noviembre chemotherapy alone.
Procesos linfoproliferativos no Hodgkin de células B
Progression to large B-cell lymphoma in splenic marginal zone lymphoma: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. However, considering the indolent course of SMZL, the therapeutic decision should be directed towards less toxic agents. Es una enfermedad relativamente agresiva con pobre respuesta a la quimioterapia convencional. After the fourth cycle of rituximab, she had achieved complete remission.
A clinicopathological study of 13 cases. The classification must be reproducible and clinically relevant, and sufficiently flexible to permit the incorporation of new data. This case demonstrates that rituximab monotherapy might also be a valid therapeutic approach in marginal zone lymphoma and autoimmune hemolytic anemia after failure of first-line treatment.
Using these 3 variables, we grouped patients into 3 prognostic categories: No existen datos que justifiquen reconocer esta variante como una enfermedad diferente. A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Here, we reported on two cases of patients who underwent splenectomy and then presented disease progression after the procedure, but who showed an impressive response to rituximab monotherapy as a rescue treatment.
All patients were assessable: One out of the three partial responders have a persistent response. N Engl J Med. After treatment, all patients had a complete resolution of splenomegaly along with restoration of their blood counts. Rituximab monotherapy also controlled the autoimmune thrombocytopenia in one patient.
En el caso de los linfomas B, estas definiciones toman aun mayor valor. Sobre todo con linfomas de bajo grado nodales primarios si afectan al bazo. Catovsky D, Matutes E.